The diagnostic significance of cardiac biomarkers in veterinary medicine by POLIZOPOULOU (Ζ.Σ. ΠΟΛΥΖΟΠΟΥΛΟΥ), Z. S.
   
   














  Copyright © 2017 Z. S. POLIZOPOULOU (Ζ.Σ.
ΠΟΛΥΖΟΠΟΥΛΟΥ) 
   
  
   
To cite this article:
POLIZOPOULOU (Ζ.Σ. ΠΟΛΥΖΟΠΟΥΛΟΥ), Z. (2017). The diagnostic significance of cardiac biomarkers in veterinary
medicine. Journal of the Hellenic Veterinary Medical Society, 65(3), 205-214. doi:https://doi.org/10.12681/jhvms.15536
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 20/02/2020 23:37:40 |
Correspondence: Z. S. Polizopoulou
Diagnostic Laboratory, Faculty of Veterinary Medicine, 
Aristotle University of Thessaloniki, 
Stavrou Voutyra 11 54627 Thessaloniki, Greece
E-mail: poliz@vet.auth.gr 
Αλληλογραφία: Ζ. Σ. Πολυζοπούλου 
Διαγνωστικό Εργαστήριο, Τμήμα Κτηνιατρικής, 
Σχολή Επιστημών Υγείας, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, 
Σταύρου Βουτυρά 11 54627 Θεσσαλονίκη
E-mail: poliz@vet.auth.gr 
Date of initial submission: 25 August 2013
Date of acceptance: 15 September 2013
Ημερομηνία αρχικής υποβολής: 25 Aυγούστου 2013 
Ημερομηνία αποδοχής: 15 Σεπτεμβρίου 2013
 
J HELLENIC VET MED SOC 2014, 65(3): 205-214
ΠΕΚΕ 2014, 65(3): 205-214
Review article
Ανασκόπηση
 The diagnostic significance of cardiac biomarkers in veterinary medicine
Polizopoulou Z. S.
Diagnostic Laboratory, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki, 
54627 Thessaloniki, Greece
  Η διαγνωστική αξία των καρδιακών βιοχημικών δεικτών στην κτηνιατρική 
πράξη
Πολυζοπούλου Ζ. Σ.
Διαγνωστικό Εργαστήριο, Τμήμα Κτηνιατρικής, Σχολή Επιστημών Υγείας, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, 
54627 Θεσσαλονίκη
ABSTRACT
Cardiac biomarkers are a group of proteins that have been extensively studied in human and veterinary medicine during the past 
decades, regarding their diagnostic and prognostic importance in heart disease. Moreover, cardiac biomarkers have been evalu-
ated for their efficacy in the assessment of clinical staging of heart disease, risk stratification of patients, selection of therapeutic 
regimens and prognosis of cases. Cardiac biomarkers are broadly classified, according to their role in the pathophysiology of 
heart failure, into markers of myocardial injury (cardiac troponins, creatine kinase MB isoenzyme), myocyte stress (natriuretic 
peptides), inflammation (acute phase proteins), cardiac remodelling (matrix metalloproteinases), neurohormonal and endothe-
lial dysfunction (endothelin, aldosterone, rennin, norepinephrine). It is unlikely that all of the aforementioned biomarkers will 
eventually be applied in clinical practice. Nevertheless, some of them (cardiac troponins, natriuretic peptides) have already been 
available commercially and established as part of the diagnostic investigation in heart disease. This review article focuses on the 
role of both established and potential cardiac biomarkers in veterinary medicine.
Keywords: Cardiac biomarkers, cat, heart disease, dog 
ΠΕΡΙΛΗΨΗ
Η χρήση των καρδιακών βιοχημικών δεικτών εφαρμόζεται σε σημαντικό βαθμό στην κτηνιατρική των ζώων συντροφιάς, εφό-
σον έχει αποδειχθεί η σημασία τους στην γρήγορη, μη επεμβατική αξιολόγηση του σταδίου της καρδιακής ανεπάρκειας και της 
κλινικής διαβάθμισης των καρδιοπαθειών. Οι καρδιακοί βιοχημικοί δείκτες ταξινομούνται σε ομάδες με βάση το παθοφυσιολο-
γικό υπόβαθρο των μεταβολών τους (εκφύλιση και νέκρωση καρδιακών μυϊκών ινών, αναδιαμόρφωση μυοκαρδίου, αιμοδυναμι-
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IntroductIon
According to the current definition standardized by the National Institute of Health (2001), “a 
biomarker is a characteristic that is objectively meas-
ured and evaluated as an indicator of normal biologi-
cal processes, pathogenic processes or pharmacologic 
responses to a therapeutic intervention”. Over the last 
two decades there has been a considerable amount of 
research in human and veterinary medicine, related to 
the use of circulating markers of cardiovascular dis-
ease in the detection of subclinical disease, the diag-
nosis of acute or chronic syndromes, the risk stratifica-
tion of patients, selection of the appropriate treatment 
and monitoring disease progression and response to 
therapy (Schober, 2005; Braunwald, 2008; Prošec 
and Ettinger, 2010). At least 40 substances have been 
identified up to date and recently classified according 
to their origin and function as markers of myocyte 
injury (leakage markers), myocyte stress (functional 
markers), cardiac remodelling, inflammation, en-
dothelial dysfunction and neurohormonal alterations 
(Braunwald, 2008; Prošec and Ettinger, 2010). It is, 
however anticipated that very few of these currently 
studied measurands will survive the test of long term 
application in clinical practice (Table 1). A review of 
all available markers is beyond the scope of this text, 
since information on newer emerging as well as older 
established markers is rapidly increasing. Instead, a 
focus on those already used or currently evaluated in 
veterinary patients is preferred. 
It has been proposed that a candidate cardiac biomar-
ker should fulfil certain criteria in order to have some 
clinical significance. Desirable features of an ideal 
biomarker should include low biological variation, 
absolute cardiospecificity, stability (in vivo and in 
vitro), adequate analytical sensitivity, accuracy and 
reproducibility of available diagnostic assays, which 
should have the potential of automation and inter-
national standardization at a reasonable cost and the 
establishment of reference ranges and cut-off values 
for each species, breed, age and gender. In addition, 
the assay should provide information superior to 
that already obtained from clinical examination and 
should contribute to the improvement of decision 
making regarding therapy and prognosis (Morrow 
and de Lemos, 2008).  
The clinical significance of cardiac biomarker evalu-
ation lies in their potential of identifying animals 
or animal populations at risk of being affected by 
specific heart diseases, with early asymptomatic/
minimally symptomatic congestive heart failure 
(CHF) or impending deterioration of cardiac func-
tion. Furthermore, information about the evolution of 
cardiac diseases could be useful for monitoring the 
efficacy of treatment (Schober, 2005)
MArKErS oF MYocYtE InJurY
Markers of myocardial integrity offer evidence of cell 
injury in the context that intracellular elements escape 
into circulation when the cell membrane is severely 
κές μεταβολές, συστηματική φλεγμονώδης αντίδραση, νευροορμονικός έλεγχος). Παρά το σημαντικό αριθμό των ερευνητικών 
μελετών που αφορούσαν πολλές από τις ουσίες αυτές, τελικά ο αριθμός των καρδιακών βιοχημικών δεικτών που απέκτησε κλι-
νική εφαρμογή στην καθημερινή πράξη είναι μικρός και περιλαμβάνει τις καρδιακές τροπονίνες (Ι και Τ) και τα νατριουρητι-
κά πεπτίδια των κόλπων και του εγκεφάλου. Στη βιβλιογραφική αυτή ανασκόπηση αναφέρονται η κλινική σημασία, οι εφαρμο-
γές των καρδιακών βιοχημικών δεικτών στην κτηνιατρική πράξη και η συμβολή τους στη διαγνωστική διερεύνηση των καρδιο-
παθειών. 
Λέξεις ευρετηρίασης: Βιοχημικοί δείκτες, γάτα, καρδιακή νόσος, σκύλος 
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cardial injury, since it is released early after the 
insult, cleared rapidly and is undetectable in nor-
mal dogs and cats (Schober, 2005; Valberg, 2008). 
Nevertheless, it is not specific for cardiac muscle 
tissue and can be found in significant amounts in 
skeletal muscles, the lungs, intestines and spleen 
(Fredericks et al., 2001; Valberg, 2008; Stockham 
and Scott, 2008). In addition, CK-MB immunoreac-
tivity is not well conserved across species and there 
are no commercially available and species-specific 
assays for use in the dog and cat (O’Brien, 1997; 
Schober, 2005). 
Lactate dehydrogenase (LD) is a cytoplasmic 
enzyme with H (heart) and M (muscle) subunits 
forming LD isoenzymes (LD 1-5).  LD 1 and 2 
also form alpha hydroxybutyrate dehydrogenase 
(a-HBDH) that has some specificity for the myo-
damaged. The pathologic changes imposed on the 
cardiac muscle in heart disease, such as pressure and 
volume overload, hypoxia, ischemia, neurohormonal 
alterations and cytokine release, lead to myocardial 
cell injury and ultimately heart failure. Analysis of 
cardiac leakage markers has progressed from the 
determination of specific enzyme activity (creatine 
kinase isoenzyme MB, lactate dehydrogenase isoen-
zymes 1 and 2), to the measurement of structural 
myofibrillary proteins (cardiac troponins I and T). 
Creatine kinase (CK) is a dimeric enzyme with M and 
B subunits, which combine to form the three isoen-
zymes CK-MM (or CK 3), CK-BB (or CK 1) and 
CK-MB (or CK 2). A fourth variant form, CK-Mt, is 
found in mitochondria of several tissues (Stockham 
and Scott, 2008). Serum CK-MB activity has been 
used in the past mainly as an indicator of acute myo-
*Modified from Braunwald, 2008
table 1. Classification of cardiac biomarkers evaluated in human and veterinary medicine*
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cardium, however both these isoenzymes have sev-
eral additional sources (erythrocytes, brain, kidneys, 
pancreas). Moreover, isoenzyme analysis requires 
special assays and interpretation of results is diffi-
cult due to interspecies variation. For these reasons 
CKMB and LD isoenzymes are no longer recom-
mended as biomarkers for the diagnosis of myo-
cardial injury in the dog and cat (Valberg, 2008; 
Stockham and Scott, 2008).
Cardiac troponins (cTn) are the most common “leak-
age” markers applied in veterinary medicine, with 
several clinical studies demonstrating their value 
in the detection of myocardial injury, regardless of 
the primary etiology (Spratt et al., 2005; Wells and 
Sleeper, 2008). The troponin complex comprises 
of myofibrillary proteins involved in the regulation 
of actin-myosin interaction and is composed of 3 
subunits, troponin C (cTnC, binding Ca+), tropon-
in I (cTnI, inhibiting tropomyosin) and troponin T 
(cTnT, binding troponin).  In the cardiac myocyte the 
majority of troponin content is structurally bound, 
whereas a smaller percentage (3-8% for cTnI and 
6-8% for cTnT) is free in the cytoplasm (Sleeper 
et al., 2001; Oyama and Sisson, 2004). A biphasic 
cTn release pattern has been suggested to occur in 
conditions causing loss of cell membrane integrity 
208 POLIZOPOULOU Z. S.
table 2. Cardiac and non-cardiac causes of increased cardiac troponins in dogs and cats
table 3. Cardiac and non-cardiac causes of increased natriuretic peptides in dogs and cats
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the deterioration of cardiac function and the over-
all prognosis (Fonfara et al., 2010; Tousoulis et al., 
2012). Recently, persistently elevated cTnI levels 
in dogs with endocardiosis were associated with 
the slowly worsening clinical status, thus indicat-
ing the advancement of heart failure. In the latter, 
increased cTnI concentration is probably attributed 
to the ongoing myocardial injury and cardiac remod-
elling lesions which follow chronic hemodynamic 
abnormalities inflicted by this condition (Tousoulis et 
al., 2012; Polizopoulou et al., 2014).
Nevertheless, and because troponins have been 
shown to increase in many cardiac and some non-
cardiac diseases (e.g. renal failure, sepsis, babesiosis, 
thromboembolism, gastric dilataion-volvulus syn-
drome), it seems than in contrast to human beings 
their role may be more important in the follow up 
and prognosis of heart disease in dogs and cats, rath-
er than in its primary diagnosis (Table 2) (Schober 
et al., 1999; Schober et al., 2002; Prošec et al., 2007; 
Prošec and Ettinger, 2010, Polizopoulou et al., 2014). 
Recently, a classification system for the interpreta-
tion of cTn results in combination with clinical scor-
ing has been proposed (Prošec and Ettinger, 2010). 
The development of high sensitivity assays for tro-
ponins will improve further their diagnostic signifi-
cance, as earlier studies had the disadvantage of high 
detection limits, raising the question on whether 
patients with mild or moderate disease had undetect-
able cTn levels and were thus misdiagnosed (Prošec 
and Ettinger, 2010). 
Another issue that has to be taken into consideration 
when interpreting cTnI results is the assay method 
and cut-off values used, because lack of standardiza-
tion inevitably causes significantly variability. This 
variation is the reason why attention must be paid 
when data and results of cTnI are interpreted and 
preferably compared with those from age matched 
healthy individuals (Schober, 2005; Adin et al., 
2006). Since it is impractical in animals to set two 
cut-off points (one representing the upper reference 
and cell necrosis (Prošec and Ettinger, 2010). Slowly 
progressing damage of the sarcomeres causes ini-
tial release of the cytosolic troponin pool, however 
if the injury continues or increases in severity the 
structurally bound amounts of cTn are also released, 
reflecting an irreversible damage to the myocardium 
(Archan and Fleisher, 2010). Cardiac troponin I is 
exclusive to the cardiac myocyte, it is immunologi-
cally different from its skeletal muscle counterpart 
and has been shown to increase more frequently 
and in the earlier stages of many small animal car-
diac diseases, when compared to cTnT (Spratt et al., 
2005; Wells and Sleeper, 2008). The serum cTnI 
concentration has been shown to correlate with the 
evolution of pathophysiologic alterations affecting 
the myocardium, clinical presentation, histopatho-
logic lesions and outcome of cases (Linklater et al., 
2007; Wells and Sleeper, 2008; Serra et al., 2010).
In dogs suffering from cardiac disease of various 
etiologies and severity there has been a correlation 
of serum cTnI concentration with the severity of 
clinical signs. In some of these studies it has been 
suggested that serial troponin assessment would offer 
an additional benefit in the management of cardiac 
patients (Linklater et al., 2007). cTnI was found to be 
useful in assessing the severity and prognosis in dogs 
suffering from a variety of congenital and acquired 
cardiac diseases (Ljungvall et al., 2008; Fonfara et 
al., 2010). In chronic heart failure, persisting tro-
ponin levels have been correlated with clinical and 
functional worsening and associated with a poor-
er prognosis and shorter survival time (Tsutamoto 
et al., 2010, Kawahara et al., 2011). Although an 
association has been found between the severity 
of myocardial damage and serum concentration of 
troponins in acute cardiac problems (e.g. infarction, 
myocarditis), this is not the case in chronic cardiac 
disease (eg mitral valve disease, dilated cardiomy-
opathy). Increases in serum cTn concentration in 
chronic cardiac diseases are more subtle, although 
serial monitoring may improve the correlation with 
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As with cTn, ANP and BNP are not specific for a 
particular heart disease, but their importance may 
lie in their use as functional markers of ongoing 
cardiac conditions (Table 3). In human medicine 
the natriuretic peptides and in particular BNP and 
NT-proBNP, are currently established parameters 
in assessing the severity and prognosis of cardiac 
disease, found also to provide greater sensitivity and 
specificity than conventional diagnostic methods. 
Thus, the clinical significance of NT-proBNP moni-
toring has been associated with improved diagnostic 
accuracy, shorter hospitalization time, prognostic 
prediction and risk stratification of patients (Januzzi 
et al., 2005; Fonarow et al., 2008; Jourdain et al., 
2007). It has been suggested that the interpretation 
of ANP and BNP concentrations could reflect the 
pathophysiology of a particular cardiac disease since 
ANP is produced mainly in the atria whereas BNP in 
the ventricles (Prošek and Ettinger, 2010). 
Guidelines for the interpretation of NT-proBNP val-
ues in dogs and cats can be retrieved from assay 
manufacturer websites (www.idexx.com), how-
ever as there is active ongoing research regarding 
the clinical applications of this test, recommenda-
tions may change after the evaluation of large num-
bers of patients. Briefly, in asymptomatic animals 
NT-proBNP values of less than 900 pmol/l (in dogs) 
or 100 pmol/l (in cats) indicate a low risk of clini-
cally significant heart disease, whereas values greater 
than the aforementioned suggest an increased prob-
ability of cardiac disease that should be further inves-
tigated with other diagnostic means (thoracic radiog-
raphy, echocardiogram, electrocardiogram). 
In veterinary medicine research on the potential 
significance and utility of NP determination has 
increased in the past few years. Circulating NP lev-
els, especially NT-proBNP and BNP, have been 
shown to correlate with the severity of cardiac dis-
ease (class of heart failure), the degree of cardiac 
remodelling (Oyama et al., 2008; Chetboul et al., 
2009; Wess et al., 2011), response to therapy, prog-
limit and one indicating clinically relevant myocar-
dial damage) it appears that the dynamic monitor-
ing of cTnI concentration could be more useful in 
assessing of myocardial dysfunction (Linklater et al., 
2007). In contrast, cTnT assays are relatively uni-
form regarding cut-off concentrations and precision 
(Serra et al., 2010). 
The diagnostic yield of cTnI may decrease in 
patients with many co-morbidities, particularly 
chronic renal failure. The pathogenesis of troponin 
elevation in chronic renal failure has been consid-
ered a multifactorial effect attributed to various 
pathomechanisms such as hypotension, cardiac 
microcirculation dysfunction, release of myotoxic 
substances, but still remains unclear (Buhaescu et 
al., 2006; Porciello et a., 2008).
MArKErS oF cArdIAc MYocYtE StrESS
The natriuretic peptides (NPs) are considered to 
be markers of increased myocyte stress (functional 
markers). They have been shown to antagonize 
the renin-angiotensin-aldosterone system (RAAS), 
protect the cardiovascular system from volume 
and pressure overload, inhibit the proliferation of 
smooth muscle cells and induce bronchodilation 
(Schober, 2005; Braunwald, 2008). Those consid-
ered to be more important from a clinical point are 
the atrial (ANP) and brain or B-type (BNP) natriu-
retic peptides. 
ANP is synthesized in the atria from its precur-
sor proANP and, responding to increased pressure 
and tension, is released in its two forms, the inac-
tive N-terminal (NT)-proANP and the biologically 
active C-terminal ANP. BNP is produced in the atria 
and to a lesser extent in the ventricles and released 
to the circulation also as the inert NT-proBNP and 
biologically active BNP forms (Braunwald, 2008). 
However, in chronic cardiac disease the ventricular 
myocardium becomes the primary source of its syn-
thesis (Moe, 2006; Prošec and Ettinger, 2010).
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nosis of outcome (Chetboul et al., 2009; Moonarmart 
et al., 2011) and even differentiate cardiac from non-
cardiac conditions in dogs (DeFrancesco et al., 2007; 
Prošek et al., 2007; Fox et al., 2009). In cats, serum 
NP monitoring has proved to be clinically useful as 
an initial screening test for suspected cardiac disease 
(Connolly et al., 2008; Wess et al., 2011).
Another potential application of NP determination 
could be the identification of patients likely to ben-
efit from vasodilator therapy (Clerico et al., 2009). 
There is still ongoing debate on whether ANP (as 
indicated by the earlier veterinary studies) or BNP 
(as suggested by more recent data) is the most appro-
priate biomarker for clinical use in the dog and cat 
(Boswood et al., 2008). In addition, there is recent 
evidence that azotemia may increase circulating NP 
levels, a factor that should be taken into consid-
eration when interpreting results in a clinical setting 
(Schmidt et al., 2009).
Other biomarkers of cardiomyocyte stress are 
adrenomedullin (a potent vasodilator, inotropic and 
natriuretic substance) and ST2 protein, a member 
of the interleukin-1 receptor family, however none 
of them has been evaluated clinically in veterinary 
medicine (Schober, 2005; Boswood, 2009). 
nEuroHorMonAL MArKErS
Endothelin, a potent vasoconstrictor substance, has 
been recognized as a neurohumoral cardiac biomar-
ker associated with heart failure (Sisson, 2004). The 
endothelin family is comprised of three related pep-
tides, ET-1, ET-2 and ET-3 that are derived from 
larger peptides in a sequence similar to that of NP 
(Sisson, 2004; Braunwald, 2008; Prošek and Ettinger, 
2010). Endothelin-1 (ET-1), a product of its precur-
sor big endothelin-1, is the predominant form of 
endothelin produced mainly by the vascular endothe-
lium. The endothelin system is activated in response 
to cardiac myocyte stretch, hypoxia, angiotensin 
II and cytokine effect (Sisson, 2004; Braunwald, 
2008; Prošek and Ettinger, 2010). Apart from its 
vasoconstrictor action, ET-1 is a growth factor for 
myocardial, endothelial and smooth muscle cells. In 
chronic heart failure neurohormoral responses aiming 
in compensating the failing myocardium also increase 
the production of ET-1 (Braunwald, 2008; Boswood, 
2009). Although initially beneficial, ET-1 mediated 
cardiac effects (activation of the renin-angiotensin-
aldosterone axis, vasopressin and the sympathetic 
nervous system) have been associated with a negative 
prognosis in human patients, signalling deteriora-
tion of myocardial function (Mc Murray et al., 1992; 
Selvais et al., 2000). Increased ET-1 levels have been 
reported in canine and feline cases of chronic heart 
failure (Prošek et al, 2004a; Prošek et al, 2004b; 
O’Sullivan et al., 2007). 
InFLAMMAtIon MArKErS
Inflammation markers have been identified to coex-
ist with heart failure for many decades, however the 
stimulus responsible for this systemic inflamma-
tory response has not been identified yet (Boswood, 
2009; Prošek and Ettinger, 2010). Various theo-
ries for its pathogenesis have been proposed, among 
them chronic adrenergic stimulation, tissue necrosis 
or underperfusion, and bacterial dissemination sec-
ondary to altered permeability of the intestinal wall 
(Anker and von Haehling, 2004; Braunwald, 2008). 
Acute phase proteins (APP) are released from hepatic 
cells after stimulation by pro-inflammatory cyto-
kines, early in the inflammatory process. In particu-
lar, C-reactive protein (CRP), a major positive APP 
in the dog, has been used as a marker for cardiovas-
cular diseases in humans and animals (Anand et al., 
2005; Rush et al., 2006; Saunders, 2009; Tousoulis et 
al., 2012).
It has been postulated that in chronic heart disease 
the damaged myocardium triggers the production of 
proinflammatory cytokines (TNF-α, interleukins 1, 6, 
18), which induce apoptosis and necrosis of cardiac 
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cells and lead to a vicious cycle with further myo-
cardial dysfunction and finally failure. Progressive 
hemodynamic overload, imbalance between pro- 
and anti-inflammatory mediators contribute to the 
establishment of heart failure (Tousoulis et al 2012). 
There is evidence both in human and veterinary med-
icine, that the increase in inflammatory markers is 
associated with clinical staging and prognosis of 
cases. In people with chronic heart failure neuro-
hormonal mediators and inflammatory cytokines 
have been shown to increase in the course of cardiac 
remodeling (Osman et al., 2006). 
Furthermore, CRP measurement has been used as a 
tool to monitor and predict the evolution of clinical 
signs in cardiac disease (Ridker, 2003). In the dog the 
half life of CRP is short, thus persistently elevated 
concentrations could be a warning sign in the man-
agement of chronic diseases like MVD (Ceron et 
al., 2005; Tecles et al., 2005). Increased CRP values 
have been recorded in dogs with acquired (Rush et 
al., 2006; Cunningham et al., 2012) and congenital 
(Saunders et al., 2009) cardiac diseases. However 
other studies failed to demonstrate that CRP could 
be a sensitive biomarker in MVD (Ljungvall et al., 
2010). Limited information exists however regarding 
the potential significance of other APP such as hapto-
globin (Hp) and ceruloplasmin (Cp) in canine cardiac 
diseases.
otHEr cArdIAc BIoMArKErS
There are several candidate cardiac biomarkers cur-
rently being investigated regarding their potential 
clinical usefulness in veterinary medicine (Table 1). 
Their future as objective and significant indicators of 
cardiac disease remains to be proven.
concLudIng rEMArKS
The clinical role of cardiac biomarkers remains to be 
further elucidated, and this applies also to the only 
two of those discussed in this text that have been 
established as useful diagnostic indicators in veteri-
nary medicine (cardiac troponins and natriuretic pep-
tides). Lessons from human medicine have pointed 
out that the combined evaluation of several markers 
could be more valuable than single ones. Practical 
issues such as the simplicity of sample handling and 
the availability of assays should not be overlooked. 
The potential role of cardiac biomarkers in the early 
identification of animals at risk of developing heart 
failure will definitely be explored in the near future 
and might prove more important than their diagnostic 
or prognostic one.
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